Summary : AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic…
Tag:
Licence
-
-
AstraZenecaDapagliflozin
NICE issues Draft Recommendation for AstraZeneca`s Forxiga (Dapagliflozin) to Treat Adults with Chronic Kidney Disease
by adminby adminAbstract: The National Institute for Health and Care Excellence (NICE) has issued an Appraisal Consultation Document (ACD) for AstraZeneca’s Forxiga (Dapagliflozin) within…